iTolerance, Inc. Completes Pre-IND Meeting with U.S. FDA for Development Program as a Potential Cure for Type 1 Diabetes Without the Need for Life-long Immunosuppression

MIAMI, FL / ACCESSWIRE / March 1, 2023 / iTolerance, Inc. ("iTolerance" or the "Company"), an early-stage regenerative medicine company developing technologies to enable tissue, organoid or cell therapy

Related Keywords

Miami ,Florida ,United States ,Dennis Riedl ,Anthony Japour ,Jenene Thomas ,Susan Roberts ,Tolerance Inc View ,Drug Administration ,Tolerance Inc ,Pre Investigational New Drug Application ,Chief Executive Officer ,Private Securities Litigation Reform Act ,Inc View ,Itolerance ,Ompletes ,Meeting ,Development ,Program ,Potential ,Cure ,Type ,Diabetes ,Without ,Need ,Life ,Song ,Immunosuppression ,